TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed metastatic colorectal adenocarcinoma~* KRAS wild-type tumors, EGFR-expressing or EGFR-nonexpressing by immunohistochemistry;~* has measurable lesion, at least 1cm in diametre by CT or MRI, at least 2cm diametre by physical examination or other iconography~* ECOG performance status 0 to 1~* Failure (disease progression/discontinuation due to toxicity) of fluoropyrimidine and oxaliplatin treatment,stop at least one month thereafter, irinotecan-naïve~Exclusion Criteria:~* Previous irinotecan or anti-EGFR therapies~* hematologic function: hemoglobin, less than 90g per liter; neutrophil count, less than 1500 per cubic millimeter; and platelet count, less than 100,000 per cubic millimeter~* liver function: bilirubin, more than 1.0 times the upper limit of normal; aspartate aminotransferase and alanine aminotransferase, more than 5.0 times and 2.5 times the upper limit of normal with hepatic metastasis or not~* Renal function: serum creatinine, more than 1.5 times the upper limit of normal~* Patients with symptomatic central nervous system metastases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CMAB009 plus Irinotecan (Type: EXPERIMENTAL): None
- Irinotecan-only and sequential-CMAB009 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months - 5 years old~* Kwashiorkor or Marasmus~* Qualifies for home-based therapeutic feeding with RUTF~Exclusion Criteria:~* Obvious congenital or other malformation that makes child a poor candidate for home-based feeding with RUTF~* Unable to consume test-dose of RUTF in clinic~* Parent refusal to participate and return for follow-up

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Amoxicillin (Type: EXPERIMENTAL): None
- cefdinir (Type: EXPERIMENTAL): cefdinir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have pain present for more than 3 months after the healing of the herpes zoster skin rash.~* At screening (V1) and enrollment (V2), patients must have a score of greater than or equal to 4 on the Pain Numeric Rating Scale (1 week recall period).~* At enrollment (V2), at least 4 pain diaries must be completed satisfactorily within the last 7 days and the average pain score must be greater than or equal to 4.~* Male or female of any race, at least 18 years of age, and using appropriate methods of contraception~Exclusion Criteria:~* Creatinine clearance \<30 mL/min (estimated from serum creatinine).~* Skin conditions in the affected dermatome that could alter sensation~* Pregabalin use in the last 30 days. Subjects taking pregabalin in the last 30 days should be washed out of pregabalin for at least 30 days prior to screening visit. Patients who had not responded to pregabalin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregablain CR tablet 82.5 to 660mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety Study of LAP-BAND Treatment for Obese Adolescents

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 14 and 17 at the time of enrollment~* Have a BMI ≥ 40 kg/m2 (with or without obesity-related co-morbid conditions) or BMI ≥ 35 kg/m2 with one or more severe co-morbid conditions~* Have a history of obesity for at least 2 years and have failed more conservative weight-reduction alternatives, such as supervised diet, exercise and behavior modification programs~Exclusion Criteria:~* Family or subject history of congenital or acquired anomalies of the gastrointestinal tract~* Severe cardiopulmonary or other serious or uncontrolled organic disease~* Severe coagulopathy; hepatic insufficiency or cirrhosis~* History of bariatric, gastric, or esophageal surgery~* History of intestinal obstruction or adhesive peritonitis~* History of esophageal dysmotility disorders~* Type I diabetes

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- LAP-BAND (Type: EXPERIMENTAL): All subjects who received the LAP-BAND System.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects, younger than 12 years old.~* Severe hemophilia B (Factor IX \[FIX\] activity of ≤ 2%).~* Body weight ≥ 10 kg.~* Subjects who have received FIX products (plasma-derived and/or recombinant FIX) for \> 150 exposure days (EDs) (6 to \< 12 years), and \> 50 EDs (\< 6 years).~* No history of FIX inhibitor formation, no detectable inhibitors at Screening and no family history of inhibitors against FIX.~* Written informed consent for study participation.~Exclusion Criteria:~* Known hypersensitivity to any FIX product or hamster protein.~* Known congenital or acquired coagulation disorder other than congenital FIX deficiency.~* Kidney or liver disease.~* Recent life-threatening bleeding episode.

- Gender: MALE
- Minimum Age: None
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- rIX-FP (Type: EXPERIMENTAL): Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Radiotherapy for Osteolymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed non-Hodgkin's lymphoma in a bony site~* Limited extraosseous disease~* Ann Arbor stage IE~* Age \>17~* ECOG performance status \<3~* Expected survival \> 6 months~* Patients capable of childbearing are using adequate contraception.~* Written informed consent~Exclusion Criteria:~* Previous radiotherapy~* Previous malignancy~* Medically unfit to undergo treatment

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* patients with type 2 diabetes, on metformin, age between 18-55 yrs, male or female~Exclusion Criteria:~* patients with type 1 diabetes, medically unstable, unacceptable clinical laboratory test results at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- PF-04937319 - Dose 1 (Type: EXPERIMENTAL): None
- PF-04937319 - Dose 2 (Type: EXPERIMENTAL): None
- PF-04937319 - Dose 3 (Type: EXPERIMENTAL): None
- PF-04937319 - Dose 4 (Type: EXPERIMENTAL): None
- Sitagliptin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Online and Shared Decision-Making Interventions to Engage Service Men and Women in Post-Deployment Mental Health Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans returning from deployment to Iraq or Afghanistan within the prior 5 years who are residing in identified study states.~Exclusion Criteria:~* Disabilities that would adversely impact ability to independently complete online screening or not allow to talk on telephone.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WEB-ED Only Control Arm (Type: NO_INTERVENTION): Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
- WEB-ED+ Treatment Arm (Type: EXPERIMENTAL): Veterans who screen positive on one or more mental health screens in WEB-ED will be RCT-eligible. RCT-consenters randomly assigned to the WEB-ED+ Treatment are will receive:~* eHealth interfaces tailored to Veterans' VA and MHV enrollment needs (links for electronic VA enrollment, MHV and MHV premium status enrollment).~* Shared decision making (SDM) interfaces: Patient Decision aids (PTSD, depression, alcohol abuse); SDM educational video; videos).~* Access to study staff available through a toll-free number to assist both Veterans and providers, including addressing questions, problem-solving about or assisting with stuck points (e.g. getting screening results to the provider).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Varenicline on D2/D3 Receptor Binding in Smokers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects will be nicotine dependent, males and females of any ethnic origin between 21 and 45 years old.~* Meet DSM-IV criteria for nicotine dependence,~* Smoke ≥10 cigarettes/day, Baseline FTND score ≥4, CO level ≥10 and are motivated to quit within 30 days of initial intake.~* Treatment seeking smokers that are willing to use varenicline as a treatment approach for their smoking cessation attempt~* No previous use of medication for smoking cessation in previous month prior inclusion.~Exclusion Criteria:~* Pregnancy (a urine pregnancy test will be performed before each PET in women)~* Trying to become pregnant or breastfeeding;~* Have abused alcohol or other drugs of abuse (cocaine, opiates, benzodiazepines, etc) in 3 months prior to randomization.~* Presence of metal objects in the body (e.g. some artificial joints, bone pins, surgical clips, skull plate, certain part of dental braces) or implanted electronic devices (e.g. cardiac pacemaker, neurostimulator), that preclude safe MR scanning.~* Claustrophobia.~* Cardiovascular or cerebrovascular diseases.~* Major psychiatric disorders including mood, anxiety or psychotic disorders with historical evidence of suicidal or homicidal behaviour.~* History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor. Gross structural brain abnormalities as revealed by T1 weighted images.~* Current use or use during the previous month of medication that may affect the CNS at the time of scanning (including illicit and non-illicit psychoactive drugs).~* Learning disability, amnesia or other conditions that impede memory and attention.~* Allergy to varenicline.~* Renal insufficiency.~* Use of other smoking cessation aids

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: EXPERIMENTAL): Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HIV-1 infection~* Age 18 or more~* Antiretroviral-naive~* Baseline CD4+ count \<100 cels/mcL.~* No mutations of drug resistance at baseline (M184V/I, K65R, resistance to efavirenz or 2 or more PRAMs (L33I/F/V, V82A/F/L/T, I84V, L90M)~* Written informed consent~Exclusion Criteria:~* Hypersensibility to study drugs.~* Pregnancy or breastfeeding~* Active OI requiring admission~* Active lymphoma or malignancy (Kaposi sarcoma included)~* Cl creatinine below 30 ml/min.~* Liver failure~* Treatment with nephrotoxic drugs, immunomodulators, interleukine-2, systemic steroids or investigational products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): tenofovir plus emtricitabine plus efavirenz
- 2 (Type: EXPERIMENTAL): tenofovir plus emtricitabine plus lopinavir-ritonavir
- 3 (Type: EXPERIMENTAL): tenofovir plus emtricitabine plus atazanavir-ritonavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapy Optimization in Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older, with a diagnosis of MS.~* Being treated with Glatiramer Acetate (GA) or (IFN)-β~* Receiving therapy from a participating Specialty Pharmacy~Exclusion Criteria:~* Has any contraindication to GA or IFN-β therapy, including pregnancy, trying to become pregnant, or breast feeding during the study~* Has received an experimental drug in the last thirty (30) days other than Fampridine SR (4-aminopyridine or 4-AP)~* Unlikely to be able to participate for the full two years of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treated MS Subjects (Type: None): Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or greater.~* Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)~* Corrected visual acuity in each eye equivalent to 20/200 or better~* Able and willing to give signed informed consent and follow study instructions.~Exclusion Criteria:~Ophthalmic:~* Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.~* Intraocular pressure \>36 mmHg~* Known hypersensitivity to any component of the formulation, latanoprost, or to topical anesthetics.~* Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s)~* Refractive surgery in study eye(s)~* Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening.~* Evidence of ocular infection and inflammation~* Clinically significant ocular disease, which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe~* Central corneal thickness greater then 600 μm~* Any abnormality preventing reliable applanation tonometry of either eye~Systemic:~* Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening.~* Clinically significant systemic disease~* Participation in any investigational study within 30 days prior to screening~* Changes in systemic medication~* Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PG324 Ophthalmic Solution 0.01% (Type: EXPERIMENTAL): Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
- PG324 Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
- Netarsudil (AR-13324) Ophthalmic Solution 0.02% (Type: ACTIVE_COMPARATOR): Netarsudil 0.02% ophthalmic solution
- Latanoprost Ophthalmic Solution 0.005% (Type: ACTIVE_COMPARATOR): Latanoprost 0.005% ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with postmenopausal osteoporosis diagnosed by DXA scanning, defined by T-score of -2.5 SD at spine or femur.~* Patients who have never received bisphosphonates therapy (bisphosphonates naive)~Exclusion Criteria:~* Inability to stand or sit in the upright position for at least 60 minutes;~* Hypersensitivity to any component of risedronate and ibandronate;~* Administration of any investigational drug within 30 days preceding the first dose of the study drug;~* Patient has been on hormone (estrogen) replacement therapy or other osteoporosis medication (e.g. SERMS and calcitonin) within the previous 3 months.~* Patient has been on systemic corticosteroids therapy for more than 1 month within the past year.~* Other bone disease except osteoporosis~* Current medical history of uncontrolled major upper GI disease

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, older than 12 months.~* Weight \> 10 kg.~* Diagnoses of uncomplicated acute P. falciparum malaria parasitaemia of up to 500 000 asexual parasite/mcl blood with axillary temperature of greater than and equal to 37.50C or history of fever.~* Documented informed consent.~* Lives close enough to the health centre for reliable follow up.~Exclusion Criteria:~* Has received anti-malarial treatment in the past 7 days.~* Is infected with other malarial species (such subjects will be excluded retrospectively).~* Severely ill (based on WHO Criteria for severe malaria ) or if patient is considered, in the opinion of the investigator or designee, to have moderately severe malaria (e.g. prostrate, repeated vomiting, dehydrated).~* Has received cotrimoxazole or chloramphenicol in the past 7 days.~* History of G6PD deficiency.~* Is pregnant.~* Has a history of allergy to any sulphonamide (for SP) or artemisinin derivative (for artesunate and co-artemether).

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete